Clinical trials
MSS clinical trials
Below are recruiting mss clinical trials, each written for real people, not researchers. We’re tracking 47 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07866313RecruitingPhase 2/Phase 3
Chemotherapy, radiation, and immunotherapy before surgery for low rectal cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy given before surgery for low rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients with a specific type of cancer that is microsatellite stable (MSS).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06613113Recruiting
Fruquintinib, adebrelimab, and radiation for advanced colorectal cancer
This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Ningbo, ZhejiangAges 18 years+ - NCT07001592RecruitingPhase 1
Injection of a modified virus for advanced GI and peritoneal cancers
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18–69 - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT04109755RecruitingPhase 2
Pembrolizumab plus radiation before surgery for rectal cancer
This trial tests whether giving pembrolizumab (an immunotherapy medicine) together with short-course radiation before surgery helps people with localized rectal cancer. It is mainly for tumors that are microsatellite stable (MSS).
GenevaAges 18 years+ - NCT05136326RecruitingPhase 2
Pre-surgery chemo-radiation for rectal cancer without MGMT
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
MilanAges 18 years+ - NCT05914389RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for colon cancer
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
Hangzhou, ZhejiangAges 18–75 - NCT05985109RecruitingPhase 2
KN 046 plus regorafenib for advanced colorectal cancer
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
BeijingAges 18 years+ - NCT06168786RecruitingPhase 2
New drug combo and radiation for advanced colorectal cancer
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–75 - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT06254521RecruitingPhase 2
Tislelizumab plus chemo before surgery for MSS rectal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Nanning, GuangxiAges 18 years+ - NCT06549907Recruiting
Study of double immunotherapy plus anti-angiogenic therapy
This trial studies people with certain types of colorectal or other solid tumors that did not respond to a single immunotherapy drug. It tests whether adding a second immune checkpoint blocker and an anti-angiogenic drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06551207Recruiting
New drug combo with radiation for advanced MSS colon cancer
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
Wuhan, HubeiAges 18–75 - NCT06566755RecruitingPhase 3
New drug combo for a common type of colorectal cancer
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Shenyang, LiaoningAges 18–75 - NCT06207656RecruitingPhase 2
Targeted therapy for BRAF V600E mutated colorectal cancer
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
MadridAges 18 years+ - NCT07559760RecruitingPhase 2
New combination therapy for advanced colorectal cancer after first treatment
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
Changchun, JilinAges 18–75 - NCT07549399RecruitingPhase 3
Radiation, Chemotherapy, and Immunotherapy for Rectal Cancer
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
Guangzhou, GuangdongAges 18–75 - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07506109RecruitingPhase 2
Study of sintilimab, ipilimumab, cetuximab, and dabrafenib for advanced colorectal cancer
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05972655RecruitingPhase 2
Testing shorter rectal radiation with chemotherapy plus immunotherapy
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hanzhou, ZhejiangAges 18–75 - NCT06522919RecruitingPhase 2
Immunotherapy and chemotherapy for advanced colorectal cancer
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
Meldola, Forlì CesenaAges 18 years+ - NCT07446322RecruitingPhase 2
Study of a new drug plus standard chemo for advanced colorectal cancer
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Homewood, AlabamaAges 18 years+ - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75
Hear when a new MSS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mss?
- Yes. Clin2 currently lists 47 recruiting mss studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mss trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mss trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.